View live charts, options flow & technicals for DexCom, Inc. →
Open Dashboard
DexCom, Inc. (DXCM) is a healthcare company in the medical devices industry with $4.97B in trailing revenue trading at a 35.4× trailing P/E — analyst consensus: strong buy.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Key Statistics
Market Cap
$33.11B
Revenue (TTM)
$4.97B
EPS (TTM)
$2.48
EPS (Fwd est.)
$3.12
Employees
11,000
Trailing P/E
35.38
Forward P/E
28.08
PEG Ratio
1.38
Price / Sales
6.66
Price / Book
12.63
EV / EBITDA
23.20
Beta (5Y)
1.42
Analyst Consensus
Consensus
Strong Buy
Analyst Price Target
+7.7% upside
Target: $94.48
Annual Revenue & Net Income
RevenueNet Income
'22
$2.91B
$340.00M
'23
$3.62B
$540.00M
'24
$4.03B
$580.00M
'25
$4.66B
$840.00M
Earnings History
Quarter
Actual EPS
Estimate
Result
Jul 2026
$0.70
$0.61
Beat (+15.1%)
Apr 2026
$0.56
$0.47
Beat (+19.0%)
Feb 2026
$0.68
$0.65
Beat (+4.5%)
Oct 2025
$0.61
$0.57
Beat (+7.5%)
Next Earnings Report
DexCom, Inc. is next expected to report earnings on 29 Oct 2026.
Profitability
62.5%
24.3%
20.1%
Gross MarginOperating MarginNet Margin
Revenue Growth (YoY)
13.1%
Return on Equity
38.5%
Return on Assets
10.3%
Balance Sheet
Cash & Equivalents
$1.95B
Total Debt
$1.40B
Net Position
$550.00M (net cash)
Free Cash Flow (TTM)
$1.02B
Debt / Equity
53.35
Share Ownership
Institutions 106.4%
Insiders 0.3%
Institutional figure exceeds 100% due to short selling
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood…
What is DXCM's market cap?
DexCom, Inc. has a market capitalization of approximately $33.11B.
What is DXCM's P/E ratio?
DexCom, Inc. trades at a trailing P/E ratio of 35.4x and a forward P/E of 28.1x, which is above the broad market average of ~25x.
How much revenue does DXCM generate?
DexCom, Inc. generated $4.97B in trailing 12-month revenue.
What do analysts say about DXCM?
The analyst consensus rating for DexCom, Inc. is strong buy, with a mean price target of $94.48. That implies +7.7% upside from the current price.
When does DXCM report earnings?
DexCom, Inc. is next scheduled to report earnings on 29 Oct 2026.
Does DXCM pay a dividend?
DexCom, Inc. does not currently pay a regular dividend.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for DexCom, Inc. on Apsis Markets.
